Lyra Therapeutics, Inc. Gains 22.22%
Fri, Apr 08, 2022 at 05:30 PM
Lyra Therapeutics, Inc. (LYRA:NASDAQ) rocketted at $5.28, representing a gain of 22.2%. The stock got featured on our News Catalysts scanner on Fri, Apr 08, 2022 at 09:52 AM in the 'PRIVATE PLACEMENT' category. From Thu, Mar 24, 2022, the stock recorded 50.00% Up Days and 36.36% Green Days
About Lyra Therapeutics, Inc. (LYRA:NASDAQ)
Lyra Therapeutics Inc a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company's technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration.
Top 10 Gainers:
- Phio Pharmaceuticals Corp. (PHIO:NASDAQ), 159.18%
- MedAvail Holdings Inc. (MDVL:NASDAQ), 39.01%
- Bicycle Therapeutics plc (BCYC:NASDAQ), 24.54%
- Poema Global Holdings Corp. (PPGH:NASDAQ), 23.69%
- Lyra Therapeutics, Inc. (LYRA:NASDAQ), 22.22%
- Aterian Inc. (ATER:NASDAQ), 21.3%
- Eastside Distilling, Inc. (EAST:NASDAQ), 20.54%
- Helix Acquisition Corp. (HLXA:NASDAQ), 19.8%
- 9F Inc. (JFU:NASDAQ), 19.79%
- TSR, Inc. (TSRI:NASDAQ), 19.72%